Codon Devices is a privately-held biotechnology company focused on enabling commercial applications of synthetic biology. Codon Devices' proprietary synthesis and design technologies improve the productivity, throughput and flexibility of its industrial, pharmaceutical and academic customers in a paradigm shift to what the company calls Constructive Biology™. The company's focus is on developing and delivering high-value products and design services in a variety of application areas, including engineered gene libraries, engineered cells that produce novel pharmaceuticals, improved vaccines, agricultural products, and biorefineries for the production of industrial chemicals and Bio-energy. Codon Devices' BioFAB™ platform uses sophisticated informatics, robotics and sequencing technologies to accurately synthesize genetic codes orders of magnitude more rapidly and cost-effectively than other currently available technology. Codon Devices is currently scaling the platform to design and construct engineered genetic devices hundreds of kilobases to megabases in length.
Founded in 2004, Codon Devices holds numerous patents and intellectual property in the area of gene engineering, and invests heavily in R&D to maintain its leadership in the field of Constructive Biology. The company's distinguished founding scientific advisory board (SAB) represents leaders in the fields of chemical, biological, and electrical engineering; molecular biology, computational biology, and genetics. Investors include Flagship Ventures, Alloy Ventures, Khosla Ventures and Kleiner Perkins Caufield and Byers.
Codon Devices is headquartered in Cambridge, MA.